The Complex Interplay of Prescription Drug Monitoring Programs, Regulated Medical Cannabis, and Chronic Pain Healthcare Visits

The increasing prevalence of chronic pain has placed a significant burden on healthcare systems worldwide. In recent years, two key developments have emerged to address this issue: prescription drug monitoring programs (PDMPs) and the legalization of medical cannabis. While these initiatives aim to improve pain management and reduce opioid misuse, their interactions and impacts on chronic pain–related healthcare visits remain complex and multifaceted. PDMPs are electronic databases that track the prescribing and dispensing of controlled substances. They have been implemented in many states in the USA to monitor opioid prescribing patterns and identify potential cases of prescription drug abuse. While PDMPs have shown some success in reducing opioid overprescribing, their impact on chronic pain–related healthcare visits still remains to be investigated. Some studies have found that PDMPs may lead to decreased access to pain care and therapy for patients with genuine needs, potentially diverting them to alternative therapies such as medical cannabis.^1,2

Medical cannabis laws have expanded rapidly in recent years, with many states in the USA and countries outside passing legislation permitting its social/recreational use while others defining its use for medical conditions, including chronic pain. Emerging evidence suggests that medical cannabis may be effective in managing certain types of chronic pain.³ However, the optimal use of medical cannabis for pain management remains an area of ongoing research and controversy. Moreover, the potential risks and benefits of medical cannabis use must always be carefully weighed against those of traditional pain medications.⁴

The intersection of PDMPs and medical cannabis laws raises several important questions. How do PDMPs interact with medical cannabis programs in terms of patient access and treatment decisions? Do PDMPs barriers facilitate patients’ seeking medical cannabis for chronic pain? Do these barriers serve necessarily the interest of the patients or perhaps they block access to proper therapy? What are the implications of such interactions for healthcare providers and patients? To address these questions, it is essential to examine the trends in chronic pain–related healthcare visits following the implementation of PDMPs and changes in medical cannabis laws. Studies have shown that PDMPs may lead to a decrease in opioid prescriptions but may also result in increased visits to emergency departments for pain-related conditions. The reasons for these changes are complex and may involve factors such as patient preferences, provider attitudes, and access to care.⁵

In their paper, Mannes et al.⁶ present a significant analysis of the interplay between PDMPs and MCLs in the context of chronic pain management. Their research employs a robust methodology, utilizing a large secondary analysis of Medicaid enrollees, which enhances the generalizability of the findings. The authors effectively analyzed the data revealing that while PDMPs alone do not significantly affect chronic pain–related healthcare visits, their enactment in conjunction with MCLs correlates with a notable reduction in such visits. This understanding is critical, as it suggests that medical cannabis laws may serve as a viable alternative for patients, potentially alleviating the burden of untreated chronic pain, and preventing exposure to the multiple adverse effects of opioids. However, the study’s conclusions regarding the effectiveness of cannabis for chronic pain management remain inconclusive, highlighting the need for further research. The implications of these findings are profound for health policy; they suggest that integrating medical cannabis laws into chronic pain management strategies could reduce reliance on opioids and probably improve patient outcomes. Policymakers should consider these results when designing regulations that aim to balance pain management needs with the risks associated with opioid use, ultimately fostering a more comprehensive approach to chronic pain treatment in the population.

In parallel to these interesting insights, it is becoming clearer that medical cannabis is penetrating chronic pain therapy either formally or informally based on the “wisdom of the crowds.” In a recent study originating from Mayo Clinic, approximately half of several thousand patients with fibromyalgia reported the use of cannabis as part of their therapeutic regimen, either licensed or purchased independently.⁷ This shift in the evolution of the clinical use of medical cannabis goes along with shifts we witness in the social, political, and medical perspectives regarding the roles medical cannabis may serve, hence generating the construct of “medicalization” of cannabis in contrast to “legalization” of its use.⁸

In conclusion, the relationship between PDMPs, medical cannabis laws, and chronic pain–related healthcare visits is complex and requires further investigation. While both PDMPs and medical cannabis have the potential to improve pain management, their interactions and impacts on healthcare systems are multifaceted. To develop effective policies and guidelines, it is essential to conduct rigorous research and engage in collaborative efforts among policymakers, healthcare providers, and patients.

Declarations

Conflict of Interest

The authors declare that they do not have a conflict of interest.